Stromal biology and therapy in pancreatic cancer
…, KK Frese, C Feig, N Cook, MA Jacobetz, MP Lolkema… - Gut, 2011 - gut.bmj.com
Pancreatic ductal adenocarcinoma (PDA) is an almost uniformly lethal disease. One
explanation for the devastating prognosis is the failure of many chemotherapies, including the …
explanation for the devastating prognosis is the failure of many chemotherapies, including the …
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
…, ME Caldwell, HI Zecchini, MP Lolkema, P Jiang… - Gut, 2013 - gut.bmj.com
Objective Pancreatic ductal adenocarcinoma (PDA) is characterised by stromal desmoplasia
and vascular dysfunction, which critically impair drug delivery. This study examines the role …
and vascular dysfunction, which critically impair drug delivery. This study examines the role …
[HTML][HTML] Pan-cancer whole-genome analyses of metastatic solid tumours
Metastatic cancer is a major cause of death and is associated with poor treatment efficacy. A
better understanding of the characteristics of late-stage cancer is required to help adapt …
better understanding of the characteristics of late-stage cancer is required to help adapt …
[PDF][PDF] Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology
MP Lolkema, CG Gadellaa-van Hooijdonk… - Journal of clinical …, 2013 - peterkapitein.nl
In the last decade, an overwhelming number of genetic aberrations have been discovered
and linked to the development of treatment for cancer. With the rapid advancement of next-…
and linked to the development of treatment for cancer. With the rapid advancement of next-…
nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
KK Frese, A Neesse, N Cook, TE Bapiro, MP Lolkema… - Cancer discovery, 2012 - AACR
Nanoparticle albumin-bound (nab)-paclitaxel, an albumin-stabilized paclitaxel formulation,
demonstrates clinical activity when administered in combination with gemcitabine in patients …
demonstrates clinical activity when administered in combination with gemcitabine in patients …
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
…, A Peer, S Kovel, A Sella, MP Lolkema… - The Lancet …, 2022 - thelancet.com
Background Metastatic castration-resistant prostate cancers are enriched for DNA repair
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …
Genetic analysis of von Hippel‐Lindau disease
…, DF Majoor‐Krakauer, MP Lolkema… - Human …, 2010 - Wiley Online Library
Mutations in the von Hippel-Lindau (VHL) gene are responsible for VHL disease, congenital
polycythemia, and are found in many sporadic tumor types as well. Reports of VHL …
polycythemia, and are found in many sporadic tumor types as well. Reports of VHL …
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
…, HJ Bloemendal, N Steeghs, MP Lolkema… - Nature …, 2019 - nature.com
The whole-genome sequencing of prospectively collected tissue biopsies from 442 patients
with metastatic breast cancer reveals that, compared to primary breast cancer, tumor …
with metastatic breast cancer reveals that, compared to primary breast cancer, tumor …
Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells
…, B De Laere, LY Dirix, RJ van Soest, MP Lolkema… - European urology, 2015 - Elsevier
… A p value <0.05 was considered statistically significant. … The reported p value is from a
log-rank test. … Lolkema received research funding from Astellas. R. Mathijssen received funding …
log-rank test. … Lolkema received research funding from Astellas. R. Mathijssen received funding …
Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer
Ionizing radiation causes DNA damage and is a mainstay for cancer treatment, but
understanding of its genomic impact is limited. We analyzed mutational spectra following …
understanding of its genomic impact is limited. We analyzed mutational spectra following …